<?xml version='1.0' encoding='utf-8'?>
<document id="32112562"><sentence text="The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study." /><sentence text="Amiodarone inhibits warfarin metabolism and is associated with major bleeding during warfarin therapy"><entity charOffset="0-10" id="DDI-PubMed.32112562.s2.e0" text="Amiodarone" /></sentence><sentence text=" Managing this drug-drug interaction (DDI) is challenging because of substantial interpatient variability in DDI magnitude" /><sentence text=" Because renal dysfunction induces changes in drug metabolism and protein binding that could alter cytochrome P450 inhibition mechanisms, we hypothesized that renal dysfunction alters the impact of the warfarin-amiodarone DDI" /><sentence text=" We tested this question in a propensity-matched cohort study of hospitalized patients with atrial fibrillation" /><sentence text=" Patients were queried from an electronic health record database" /><sentence text=" Renal function was estimated with creatinine clearance (CrCl)"><entity charOffset="35-45" id="DDI-PubMed.32112562.s7.e0" text="creatinine" /></sentence><sentence text=" Warfarin response was measured with the warfarin sensitivity index (WSI), a dose-normalized international normalized ratio (INR) measure, and was modeled with multilevel mixed-effects linear regression" /><sentence text=" Time to supratherapeutic INR (&gt; 4) was modeled using Cox regression" /><sentence text=" Propensity score matching resulted in 4,518 patients administered amiodarone and 4,518 controls"><entity charOffset="67-77" id="DDI-PubMed.32112562.s10.e0" text="amiodarone" /></sentence><sentence text=" Amiodarone's effect on warfarin response varied threefold across the renal function range, increasing WSI by 36% in patients with normal renal function (CrCl 115 mL/minute), but by only 11" /><sentence text="8% in patients with severe renal dysfunction (CrCl 15 mL/minute)" /><sentence text=" Similarly, amiodarone had a strong effect in patients with normal renal function (hazard ratio (HR) 1"><entity charOffset="12-22" id="DDI-PubMed.32112562.s13.e0" text="amiodarone" /></sentence><sentence text="80; 1" /><sentence text="23, 2" /><sentence text="64), but a negligible effect on supratherapeutic INR hazard in patients with severe renal dysfunction (HR 1" /><sentence text="01; 0" /><sentence text="75, 1" /><sentence text="37)" /><sentence text=" These results suggest that renal function is a novel factor that explains substantial variability in the warfarin-amiodarone DDI" /><sentence text=" This information could inform warfarin dosage adjustment and monitoring and may have implications for the selection of oral anticoagulation agents in patients treated with amiodarone"><entity charOffset="173-183" id="DDI-PubMed.32112562.s21.e0" text="amiodarone" /></sentence><sentence text="" /></document>